Merck (MRK) Goodwill & Intangibles (2009 - 2026)
Merck (MRK) posted quarterly Goodwill & Intangibles of $47.3 billion for Q1 2026, up 26.4% year-over-year from $37.4 billion in Q1 2025, and down 1.94% quarter-over-quarter from $48.3 billion in Q4 2025.
Merck (MRK) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Goodwill & Intangibles for 18 consecutive years, with $47.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 26.4% year-over-year to $47.3 billion; the TTM figure through Mar 2026 stood at $47.3 billion (up 26.4% YoY), while the FY2025 annual figure was $48.3 billion, up 26.87% from the prior year.
- Goodwill & Intangibles fell to $47.3 billion in Q1 2026 per MRK's latest filing, from $48.3 billion in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $48.3 billion in Q4 2025 and bottomed at $36.8 billion in Q2 2025.
- Historically, Goodwill & Intangibles has averaged $40.8 billion across 5 years, with a median of $40.4 billion in 2023.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles soared 34.51% — and 2023, when it decreased 7.26%.
- Merck's Goodwill & Intangibles stood at $41.5 billion in 2022, then fell by 5.46% to $39.2 billion in 2023, then slipped by 2.98% to $38.0 billion in 2024, then gained by 26.87% to $48.3 billion in 2025, then declined by 1.94% to $47.3 billion in 2026.
- Business Quant data shows MRK's Goodwill & Intangibles at $47.3 billion in Q1 2026, $48.3 billion in Q4 2025, and $36.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.56 Bn |
| Mar 31, 2026 | 47.33 Bn |
| Dec 31, 2025 | 48.26 Bn |
| Sep 30, 2025 | 36.90 Bn |
| Jun 30, 2025 | 36.78 Bn |
| Mar 31, 2025 | 37.44 Bn |
| Dec 31, 2024 | 38.04 Bn |
| Sep 30, 2024 | 38.71 Bn |
| Jun 30, 2024 | 38.15 Bn |
| Mar 31, 2024 | 38.75 Bn |
| Dec 31, 2023 | 39.21 Bn |
| Sep 30, 2023 | 40.38 Bn |
| Jun 30, 2023 | 40.86 Bn |
| Mar 31, 2023 | 41.07 Bn |
| Dec 31, 2022 | 41.47 Bn |
| Sep 30, 2022 | 42.53 Bn |
| Jun 30, 2022 | 43.71 Bn |
| Mar 31, 2022 | 44.28 Bn |
| Dec 31, 2021 | 44.20 Bn |
| Sep 30, 2021 | 32.25 Bn |